bioLOGIC Europe 2007--Terrapinn's eighth annual conference.
Mackay
Janie
J
Thomson Scientific, 77 Hatton Garden, London, EC1N 8JS, UK. janie.mackay@thomson.com
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D001691:Biological Therapy / Q000379:methods* / Q000639:trends; D017277:Drug Approval; D004345:Drug Industry / Q000379:methods / Q000639:trends; D005060:Europe; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D008268:Macular Degeneration / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy; D010330:Patents as Topic; D011994:Recombinant Proteins / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D014481:United States
D000911:Antibodies, Monoclonal; D011994:Recombinant Proteins